Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Foghorn Therapeutics (FHTX) Shares Issued: 2020-2025

Historic Shares Issued for Foghorn Therapeutics (FHTX) over the last 5 years, with Sep 2025 value amounting to $49,000.

  • Foghorn Therapeutics' Shares Issued was N/A to $49,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $102.7 million, marking a year-over-year change of. This contributed to the annual value of $103.4 million for FY2024, which is 5715.58% up from last year.
  • Latest data reveals that Foghorn Therapeutics reported Shares Issued of $49,000 as of Q3 2025, which was down 80.71% from $254,000 recorded in Q2 2025.
  • Foghorn Therapeutics' 5-year Shares Issued high stood at $102.2 million for Q2 2024, and its period low was $16,000 during Q4 2022.
  • Its 3-year average for Shares Issued is $11.7 million, with a median of $186,000 in 2023.
  • In the last 5 years, Foghorn Therapeutics' Shares Issued plummeted by 99.96% in 2022 and then spiked by 99,156.31% in 2024.
  • Over the past 5 years, Foghorn Therapeutics' Shares Issued (Quarterly) stood at $41.5 million in 2021, then crashed by 99.96% to $16,000 in 2022, then skyrocketed by 1,062.50% to $186,000 in 2023, then soared by 99,156.31% to $102.2 million in 2024, then crashed by 99.75% to $49,000 in 2025.
  • Its Shares Issued stands at $49,000 for Q3 2025, versus $254,000 for Q2 2025 and $139,000 for Q1 2025.